DK0764020T3 - Transdermalt system til indgivelse af lægemiddel - Google Patents
Transdermalt system til indgivelse af lægemiddelInfo
- Publication number
- DK0764020T3 DK0764020T3 DK95922554T DK95922554T DK0764020T3 DK 0764020 T3 DK0764020 T3 DK 0764020T3 DK 95922554 T DK95922554 T DK 95922554T DK 95922554 T DK95922554 T DK 95922554T DK 0764020 T3 DK0764020 T3 DK 0764020T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapeutic agent
- pct
- cyclodextrin
- date jan
- sec
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9413866A GB2290964A (en) | 1994-07-08 | 1994-07-08 | Transdermal drug delivery system |
PCT/FI1995/000358 WO1996001626A1 (en) | 1994-07-08 | 1995-06-20 | Transdermal drug delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0764020T3 true DK0764020T3 (da) | 1999-10-18 |
Family
ID=10758074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95922554T DK0764020T3 (da) | 1994-07-08 | 1995-06-20 | Transdermalt system til indgivelse af lægemiddel |
Country Status (12)
Country | Link |
---|---|
US (1) | US5817332A (da) |
EP (1) | EP0764020B1 (da) |
JP (1) | JP3734267B2 (da) |
AT (1) | ATE178485T1 (da) |
AU (1) | AU2740595A (da) |
CA (1) | CA2193129C (da) |
DE (1) | DE69508938T2 (da) |
DK (1) | DK0764020T3 (da) |
ES (1) | ES2130622T3 (da) |
GB (1) | GB2290964A (da) |
GR (1) | GR3030369T3 (da) |
WO (1) | WO1996001626A1 (da) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19980033113A (ko) * | 1996-10-25 | 1998-07-25 | 야스다케 히지 | 국소 마취제 수용액, 국소 마취제의 용해도를 개선시키는 방법, 신경독성이 감소된 국소 마취제 및 국소 마취제의 신경 독성을 감소시키는 방법 |
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
DE19810951B4 (de) * | 1998-03-13 | 2005-09-29 | Ciba Speciality Chemicals Holding Inc. | Verwendung eines textilen Materials als transdermales Abgabesystem sowie Verfahren zu seiner Herstellung |
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE19814087A1 (de) * | 1998-03-30 | 1999-10-14 | Lohmann Therapie Syst Lts | Feuchtigkeitsaktivierbares therapeutisches System |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
US6586000B2 (en) | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US20030104041A1 (en) * | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
US6673363B2 (en) | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
US6719997B2 (en) | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
US6582724B2 (en) | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
ATE290856T1 (de) * | 1999-12-16 | 2005-04-15 | Dermatrends Inc | Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit |
US6689378B1 (en) | 1999-12-28 | 2004-02-10 | Kimberly-Clark Worldwide, Inc. | Cyclodextrins covalently bound to polysaccharides |
US7179483B2 (en) | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US6878693B2 (en) * | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
IL163685A0 (en) | 2002-02-25 | 2005-12-18 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
ES2293193T5 (es) | 2004-07-13 | 2012-06-13 | Bayer Schering Pharma Oy | Sistema de suministro retardado con descarga inicial controlada |
EA017982B1 (ru) | 2005-02-24 | 2013-04-30 | ДИФФЬЮЖН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи | Фармацевтическая композиция на основе транскаротиноидов и способы лечения опухоли |
WO2006135785A2 (en) * | 2005-06-10 | 2006-12-21 | Medical College Of Georgia Research Institute | Compositions and methods for treating immune disorders |
US9446017B2 (en) | 2005-08-11 | 2016-09-20 | Augusta University Research Institute, Inc. | Compositions and methods for treating herpes simplex virus |
CA2648742A1 (en) * | 2006-04-07 | 2007-10-18 | Allergan, Inc. | Compositions including relatively water insoluble/unwettable drugs and methods for using same |
US9114133B2 (en) | 2006-08-25 | 2015-08-25 | U.S. Dept. Of Veterans Affairs | Method of improving diastolic dysfunction |
EP2146948A4 (en) | 2007-04-13 | 2010-08-04 | Diffusion Pharmaceuticals Llc | USE OF BIPOLAR TRANS-CAROTINOIDES AS PRE-TREATMENT AND TREATMENT OF PERIPHERAL VASCULAR DISEASE |
AU2008319225B2 (en) * | 2007-10-31 | 2016-09-29 | Diffusion Pharmaceuticals Llc | A new class of therapeutics that enhance small molecule diffusion |
US10130689B2 (en) | 2009-06-22 | 2018-11-20 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
US20130017188A1 (en) | 2009-07-31 | 2013-01-17 | The Brigham And Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
EP2556082B1 (en) | 2010-04-08 | 2017-02-22 | Emory University | Substituted androst-4-ene diones |
EP2575487B1 (en) | 2010-06-02 | 2017-10-18 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
US9585930B2 (en) | 2011-03-20 | 2017-03-07 | Trustees Of Boston University | Therapeutic agent for emphysema and COPD |
US9480696B2 (en) | 2011-05-04 | 2016-11-01 | Trustees Of Boston University | Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
EP2543370A1 (en) | 2011-07-06 | 2013-01-09 | Georgia Health Sciences University Research Institute, Inc. | Compositions and Methods for Treating Herpes Simplex Virus |
US9243037B2 (en) | 2011-11-10 | 2016-01-26 | Trustees Of Boston College | Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity |
WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
CA2924141C (en) | 2013-08-22 | 2022-06-07 | The General Hospital Corporation | 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase |
EP3038625A4 (en) | 2013-08-29 | 2017-08-23 | Trustees of Boston University | Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections |
CN105764496B (zh) | 2013-10-07 | 2020-09-25 | 帝国制药美国公司 | 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物 |
KR101891186B1 (ko) * | 2013-10-07 | 2018-08-24 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 조성물을 포함하는 통증을 관리하기 위한 방법 및 조성물 |
KR101831290B1 (ko) | 2013-10-07 | 2018-02-22 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물 |
TWI704933B (zh) | 2013-10-07 | 2020-09-21 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
BR112016014404A2 (pt) * | 2013-12-18 | 2017-08-08 | Gnt Llc | Composições e métodos para tratamento de glaucoma |
US9974754B2 (en) | 2013-12-18 | 2018-05-22 | Maruishi Pharmaceutical Co., Ltd. | Hydrous adhesive patch |
EP3303286B1 (en) | 2015-06-01 | 2023-10-04 | Cedars-Sinai Medical Center | Compounds that bind to rela of nf-kb for use in treating cancer |
MX2018001075A (es) | 2015-07-28 | 2019-04-15 | Vyome Therapeutics Ltd | Agentes terapeuticos y profilacticos antibacterianos. |
US10493049B2 (en) | 2016-02-10 | 2019-12-03 | Niracle LLC | Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations |
EP3432929A4 (en) | 2016-03-24 | 2019-11-27 | Diffusion Pharmaceuticals LLC | USE OF BIPOLAR TRANSCAROTINOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR THE TREATMENT OF CANCER |
EP4371554A3 (en) | 2016-12-31 | 2024-08-07 | BioXcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
SG11202012772XA (en) | 2018-06-27 | 2021-01-28 | Bioxcel Therapeutics Inc | Film formulations containing dexmedetomidine and methods of producing them |
TWI772807B (zh) | 2019-05-27 | 2022-08-01 | 日商救急藥品工業股份有限公司 | 外用製劑 |
WO2021016112A2 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
US11844753B2 (en) | 2021-11-08 | 2023-12-19 | Weiyong Li | Transdermal drug delivery system for delivering a drug to a patient |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4756710A (en) * | 1985-04-05 | 1988-07-12 | Merck & Co., Inc. | pH-Mediated drug delivery system |
US4749574A (en) * | 1986-04-14 | 1988-06-07 | Fujisawa Pharmaceutical Co., Ltd. | Sustained-release transdermal delivery preparations |
US4781924A (en) * | 1987-11-09 | 1988-11-01 | Alza Corporation | Transdermal drug delivery device |
SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
HU210921B (en) * | 1990-03-28 | 1995-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them |
GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
GB9111732D0 (en) * | 1991-05-31 | 1991-07-24 | Orion Yhtymae Oy | The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs |
AU661726B2 (en) * | 1991-10-16 | 1995-08-03 | Timo Petteri Paronen | Peroral drug delivery system |
US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
-
1994
- 1994-07-08 GB GB9413866A patent/GB2290964A/en not_active Withdrawn
-
1995
- 1995-06-20 JP JP50413396A patent/JP3734267B2/ja not_active Expired - Lifetime
- 1995-06-20 CA CA002193129A patent/CA2193129C/en not_active Expired - Lifetime
- 1995-06-20 AU AU27405/95A patent/AU2740595A/en not_active Abandoned
- 1995-06-20 US US08/765,766 patent/US5817332A/en not_active Expired - Lifetime
- 1995-06-20 DE DE69508938T patent/DE69508938T2/de not_active Expired - Lifetime
- 1995-06-20 ES ES95922554T patent/ES2130622T3/es not_active Expired - Lifetime
- 1995-06-20 AT AT95922554T patent/ATE178485T1/de active
- 1995-06-20 EP EP95922554A patent/EP0764020B1/en not_active Expired - Lifetime
- 1995-06-20 DK DK95922554T patent/DK0764020T3/da active
- 1995-06-20 WO PCT/FI1995/000358 patent/WO1996001626A1/en active IP Right Grant
-
1999
- 1999-05-28 GR GR990401461T patent/GR3030369T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO1996001626A1 (en) | 1996-01-25 |
EP0764020A1 (en) | 1997-03-26 |
GB2290964A (en) | 1996-01-17 |
EP0764020B1 (en) | 1999-04-07 |
ATE178485T1 (de) | 1999-04-15 |
DE69508938D1 (de) | 1999-05-12 |
US5817332A (en) | 1998-10-06 |
GR3030369T3 (en) | 1999-09-30 |
AU2740595A (en) | 1996-02-09 |
JPH10502388A (ja) | 1998-03-03 |
DE69508938T2 (de) | 1999-09-16 |
JP3734267B2 (ja) | 2006-01-11 |
ES2130622T3 (es) | 1999-07-01 |
CA2193129C (en) | 2007-11-06 |
GB9413866D0 (en) | 1994-08-24 |
CA2193129A1 (en) | 1996-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0764020T3 (da) | Transdermalt system til indgivelse af lægemiddel | |
RS52577B (en) | ONE-DAY OXYCODON FORMULATIONS | |
ATE267798T1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
ATE237330T1 (de) | Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung | |
MX2008000099A (es) | Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones. | |
ATE298259T1 (de) | Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle | |
UA41446C2 (uk) | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі | |
NZ520083A (en) | The modification of a patient's blood with ultra-violet light for the treatment of congestive heart failure | |
ATE198152T1 (de) | Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe | |
FI950319A0 (fi) | Säädellyn vapautumisnopeuden omaava morfiinivalmiste | |
TR200001998T1 (tr) | Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu | |
CY1107452T1 (el) | Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων | |
CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
ATE202923T1 (de) | Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle | |
CY1107496T1 (el) | Ρυθμισμενες συνθεσεις για διαλυση | |
GEP20053501B (en) | Core Tablet for Controlled Release of Gliclazide after Oral Administration | |
BR0010618A (pt) | Sistema terapêutico transdermal (tts), que contém tolterodina | |
ATE260658T1 (de) | Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen | |
DE69133623D1 (de) | Haltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung | |
ID28160A (id) | Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat. | |
ATE388687T1 (de) | Medikamentöse verabreichung von nikotin in form von kaugummi | |
DK0856312T3 (da) | Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme | |
ATE464878T1 (de) | Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl | |
BR0111158A (pt) | Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente | |
DK1237562T3 (da) | Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme |